Punturi, Nindo B.
Seker, Sinem
Devarakonda, Vaishnavi
Mazumder, Aloran
Kalra, Rashi
Chen, Ching Hui http://orcid.org/0000-0002-8365-3036
Li, Shunqiang
Primeau, Tina
Ellis, Matthew J.
Kavuri, Shyam M. http://orcid.org/0000-0002-3321-6727
Haricharan, Svasti http://orcid.org/0000-0002-4471-8853
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA229613, U10CA180821, U10CA180882, U24C196171)
U.S. Department of Defense (W81XWH-18-1-0034, W81XWH-18-1-0035)
Susan G. Komen (PG12220321)
Cancer Prevention and Research Institute of Texas (RR140033)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 15 September 2020
Accepted: 22 April 2021
First Online: 19 May 2021
Competing interests
: M.J.E. has intellectual property ownership and received royalties for the PAM50-based breast cancer test “Prosigna.” In the last 5 years he has received ad hoc consulting fees and meals (<$5000 per year) from Abbvie, Novartis, AstraZenica, Pfizer, Sermonix, and Puma. S.M.K. is a stakeholder in NeoZenome Therapeutics Inc. S.L. has received license fee from Envigo. He received research funding from Pfizer, Takeda Oncology, Zenopharm, NIH, and DOD, outside of this project. The other authors declare no competing interests.